ADC Therapeutics (ADCT) Other Non-Current Liabilities (2020 - 2026)

ADC Therapeutics has disclosed Other Non-Current Liabilities across 7 years of filings, most recently posting $18.5 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $18.5 million, up 316.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.5 million (up 316.1% YoY), and the FY2024 annual result was $2.4 million, down 72.6% from the prior year.
• Other Non-Current Liabilities came in at $18.5 million for Q1 2026 at ADC Therapeutics, up from $9.4 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $18.5 million in Q1 2026 to a low of $838000.0 in Q4 2022.
• The 5-year median for Other Non-Current Liabilities is $6.9 million (2024), against an average of $7.2 million.
• Across the five-year window, Other Non-Current Liabilities sank 99.62% in 2022 and surged 959.55% in 2023, its largest moves.
• ADC Therapeutics' Other Non-Current Liabilities stood at $838000.0 in 2022, then soared by 959.55% to $8.9 million in 2023, then sank by 72.6% to $2.4 million in 2024, then surged by 286.11% to $9.4 million in 2025, then soared by 96.93% to $18.5 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $18.5 million (Q1 2026), $9.4 million (Q3 2025), and $7.2 million (Q2 2025), per Business Quant data.